在实用性PRIORITIZE研究中获得持续病毒学应答的丙型肝炎患者的长期随访
该分析描述PRIORITIZE研究中获得持续病毒学应答(SVR)的无肝硬化丙型肝炎患者长期随访情况,包括实验室检测与影像学检查频率、肝功能指标变化、肝失代偿或肝细胞癌(HCC)及死亡的发生,以及SVR的持久性。
要点
- 分析对象为PRIORITIZE研究中获得SVR的无肝硬化丙型肝炎患者。
- 随访内容包括实验室检测与影像学检查频率及肝功能指标变化。
- 观察结局包括肝失代偿、肝细胞癌、死亡及SVR持久性。
研究设计与样本
- 基于实用性PRIORITIZE研究的长期随访分析,纳入获得持续病毒学应答(SVR)的丙型肝炎患者(分析目标人群包括无肝硬化者)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple real-world studies have confirmed the safety and efficacy of hepatitis C (HCV) direct-acting antivirals (DAAs); however, few studies have provided data on long-term outcomes of patients without cirrhosis after achieving sustained virologic response (SVR).1-3 The aims of this analysis were to describe, among individuals in the PRIORITIZE Study achieving SVR: (1) the frequency of laboratory testing and imaging during long-term follow-up (LTFU), (2) changes in liver tests, (3) occurrence of hepatic decompensation or hepatocellular carcinoma (HCC) and deaths, and (4) durability of SVR.
引用
- Lok AS, Moon J, Sherman KE, et al. Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study. Clin Gastroenterol Hepatol. 2022. PMID: 35182741. doi:10.1016/j.cgh.2022.01.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。